Clinical Trials · Preventive Cardiology

ZEUS Trial: Ziltivekimab Fails to Cut MACE, Reigniting the Inflammation Debate

A clean biological signal met a flat clinical curve, and the residual-inflammation hypothesis now faces its most consequential stress test yet.

For physicians and physician-investors · August 2026

Ziltivekimab, an investigational interleukin-6 (IL-6) ligand inhibitor, did not reduce major adverse cardiovascular events (MACE) relative to placebo in the phase 3 ZEUS trial.

Topline results, released by drugmaker Novo Nordisk on July 31, 2026, showed a hazard ratio of 0.99 (95% CI 0.88–1.11) for the composite of cardiovascular death, nonfatal MI, or nonfatal stroke.

The result lands despite clear pharmacodynamic success, as ziltivekimab produced the expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP).

For an interventional and preventive cardiology audience already weighing whether to act on residual inflammatory risk, ZEUS forces a hard question: does biomarker modulation without outcome benefit undercut the inflammatory hypothesis of atherosclerosis, or simply indict this particular molecule in this particular population?

Trial Design and Topline Findings

ZEUS was a double-blind, placebo-controlled outcomes trial enrolling more than 6,300 adults with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and hsCRP levels of 2 mg/L or higher.

Participants received once-monthly subcutaneous ziltivekimab 15 mg or placebo on top of standard of care.

The fully human monoclonal antibody binds free IL-6, a proximal driver of the hepatic acute-phase response and a cytokine long implicated in plaque instability.

Despite achieving robust target engagement, the biological effect did not translate into a lower rate of the three-point MACE endpoint.

Overall adverse events, serious adverse events, and all-cause mortality were similar between arms.

Consistent with the known class effect of IL-6 pathway blockade, serious infections occurred more frequently with ziltivekimab than with placebo.

Two additional outcomes trials, HERMES in heart failure with preserved ejection fraction and ARTEMIS in post-MI patients, will proceed as planned, with readouts anticipated in the first half of 2027.

Full ZEUS results, including secondary and safety endpoints, are expected at a scientific meeting later in 2026.

Figure 1. Point estimates for MACE hazard ratios across major anti-inflammatory cardiovascular outcomes trials. Teal markers denote neutral trials; amber markers denote trials meeting their primary endpoint. Approximate values for illustration; consult primary sources for exact confidence intervals.

A Recurring Pattern: Target Engagement Without Outcome Benefit

ZEUS is not the first cardiovascular inflammation trial to separate biomarker response from clinical benefit.

CLEAR SYNERGY (OASIS 9), presented in late 2024, found that routine colchicine 0.5 mg daily did not reduce the composite of CV death, MI, stroke, or ischemia-driven revascularization when started within 72 hours of PCI for acute MI, despite a significantly larger CRP reduction in the colchicine arm.

That result stood in contrast to two earlier positive trials, COLCOT and LoDoCo2, which together underpinned the 2023 FDA approval of low-dose colchicine as the first anti-inflammatory agent indicated for cardiovascular risk reduction.

A parallel story played out with canakinumab, an interleukin-1β inhibitor that reduced MACE in the CANTOS trial among post-MI patients with elevated hsCRP, only for its manufacturer to abandon the cardiovascular indication after regulators requested additional safety and net-benefit data.

Across these programs, the common thread is a drug that reliably lowers hsCRP without a consistent, reproducible reduction in hard cardiovascular endpoints across settings and populations.

The 2025 American College of Cardiology scientific statement on inflammation and cardiovascular disease had characterized the evidence linking inflammation to ASCVD as clinically actionable and endorsed hsCRP testing alongside LDL-C in both primary and secondary prevention.

ZEUS does not overturn the prognostic value of hsCRP, but it does sharpen the distinction between hsCRP as a risk marker and IL-6 inhibition as a proven therapeutic strategy.

Why the Signal Might Be Missing

Several explanations are circulating among trialists and are worth weighing rather than treating the inflammatory hypothesis as disproven outright.

One possibility is population selection, since ASCVD-plus-CKD patients carry a mix of atherosclerotic and non-atherosclerotic risk that IL-6 blockade may not adequately address.

A second is timing, as chronic low-grade inflammation in stable outpatients may respond differently to cytokine blockade than the acute inflammatory surge following plaque rupture, a distinction also raised to explain the divergent CLEAR SYNERGY and LoDoCo2 results.

A third is competing risk from the infection signal, since any cardiovascular benefit from reduced plaque inflammation could be partially offset by increased infection-related morbidity in an immunosuppressed cohort.

A fourth is that free IL-6 and hsCRP reduction, while biologically reassuring, may not be adequate surrogates for the specific inflammatory pathways that drive plaque rupture and thrombosis.

Illustrative Case

A 68-year-old with prior MI, PCI to the LAD three years ago, and stage 3a CKD (eGFR 52) presents for a routine follow-up on high-intensity statin and a PCSK9 inhibitor, with LDL-C at goal but hsCRP persistently elevated at 4.2 mg/L on two occasions.

Before ZEUS, this profile might have prompted discussion of an investigational IL-6-targeted approach or reinforced consideration of low-dose colchicine for residual inflammatory risk.

After ZEUS, the practical takeaway is unchanged for colchicine, which retains its FDA indication and guideline standing for chronic, stable ASCVD outside the acute post-MI window studied in CLEAR SYNERGY, while ziltivekimab remains strictly investigational with no near-term path to clinical use in this population.

Agents Targeting the Inflammatory Pathway

Table 1. Selected anti-inflammatory agents studied for cardiovascular risk reduction

Agent	Target	Key CV Trial	CV Outcome	Regulatory Status (CV)
Colchicine (Lodoco, Colcrys, generic; Agepha Pharma/generics)	Microtubule/NLRP3 inflammasome	LoDoCo2, COLCOT; CLEAR SYNERGY neutral in acute post-MI PCI	Positive in chronic stable ASCVD; neutral in acute post-MI	FDA-approved (2023) for established ASCVD/risk reduction
Canakinumab (Ilaris; Novartis, NYSE: NVS)	IL-1β	CANTOS	Positive for MACE in post-MI patients with elevated hsCRP	No CV indication pursued; approved only for autoinflammatory conditions
Ziltivekimab (investigational; Novo Nordisk, NYSE: NVO)	Free IL-6 ligand	ZEUS	Neutral for MACE despite hsCRP/IL-6 reduction	Investigational; not approved for any indication

Financial and Pipeline Context

Novo Nordisk stated the ZEUS outcome will not alter its previously communicated 2026 adjusted operating profit outlook, though it will trigger a non-cash impairment charge in the third quarter of 2026.

As of early August 2026, analyst consensus on Novo Nordisk (NYSE: NVO) was rated a moderate "Buy," with a roughly $47 twelve-month consensus price target reported by aggregated sell-side coverage.

Given that GLP-1 receptor agonists dominate Novo Nordisk's revenue base, the ZEUS readout is a pipeline setback rather than a material threat to the company's near-term financial trajectory, and HERMES/ARTEMIS remain the more consequential ziltivekimab catalysts to watch into 2027.

Colchicine pricing varies substantially by formulation and pharmacy, with generic 0.6 mg colchicine available for roughly $15 to $30 for a 30-tablet supply through GoodRx coupons, while the branded cardiovascular-indicated formulation, Lodoco, carries substantially higher list pricing without a generic alternative currently available.

Stock prices, analyst ratings, and drug pricing shift frequently and should be independently verified before any clinical-financial correlation is drawn.

Clinical Trial Landscape at a Glance

Table 2. Anti-inflammatory cardiovascular outcomes trials: population and design

Trial	Population	N	Comparator	Primary Result
ZEUS	ASCVD + CKD + hsCRP ≥2 mg/L	>6,300	Ziltivekimab 15 mg monthly vs placebo	Neutral (HR 0.99)
CLEAR SYNERGY (OASIS 9)	Acute MI within 72h of PCI	7,062	Colchicine 0.5 mg daily vs placebo	Neutral (HR 0.99)
LoDoCo2	Chronic coronary disease	5,522	Colchicine 0.5 mg daily vs placebo	Positive
COLCOT	Recent MI (≤30 days)	4,745	Colchicine 0.5 mg daily vs placebo	Positive
CANTOS	Prior MI + hsCRP ≥2 mg/L	10,061	Canakinumab (3 doses) vs placebo	Positive at 150 mg dose

Bottom Line

Ziltivekimab achieved clean target engagement in ZEUS but produced no reduction in MACE among patients with ASCVD, CKD, and elevated hsCRP, joining CLEAR SYNERGY and the canakinumab CV-indication withdrawal as further evidence that lowering inflammatory biomarkers does not guarantee a clinical outcome benefit.

Colchicine's FDA-approved indication for chronic, stable ASCVD is unaffected by ZEUS, and hsCRP retains prognostic value, but the bar for a new anti-inflammatory agent to change practice just moved higher, not lower.

HERMES and ARTEMIS, reading out in 2027, will determine whether IL-6 inhibition has a future in heart failure or post-MI populations even after this ASCVD/CKD miss.

Physician education disclaimer: This article is intended for licensed healthcare professionals for educational purposes and does not constitute clinical practice guidance. Treatment decisions should be individualized and based on current FDA labeling, professional society guidelines, and the clinical judgment of the treating physician.

Financial disclaimer: This content is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Stock prices, analyst ratings, and drug pricing are time-sensitive, approximate, and subject to change; verify current data independently before making any financial decision. The author is not a licensed financial advisor.

References

1. Novo Nordisk. Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation. Press release. July 31, 2026.
2. TCTMD. ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients. August 3, 2026.
3. TCTMD. Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows. October 29, 2024.
4. American College of Cardiology. New ACC Scientific Statement Details Role of Inflammation in CVD. September 29, 2025.
5. TCTMD. Hopes Fade for a CV Indication for Canakinumab: What's Next for the Inflammatory Hypothesis?
6. ClinicalTrials.gov. HERMES (NCT05636176) and ARTEMIS (NCT06118281) trial registrations.

Further Viewing

• Targeting Inflammation in Cardiovascular Disease: From Canakinumab to Colchicine — Cardiology Rounds lecture.
• Antiinflammatory Therapy and Cardiovascular Events — CANTOS trial overview.
• LoDoCo2 – Low-Dose Colchicine in Coronary Disease — ESC Congress 2020 discussion.

© 2026. All trial data current as of publication date; consult primary sources for full results when published.

July 2026 Cardiology Updates: Statins for Half of America, a Pill That Acts Like an Injection, and TAVI's Long Game

A synthesis of the highest-yield July 2026 cardiovascular readouts for the practicing and investing physician.

Physician-Investor Cardiology Digest · Cardiovascular Medicine & Markets · July 2026 Update, published August 2026

This roundup of July 2026 cardiology updates covers the month's highest-yield readouts across prevention, heart failure, structural heart, and AI-enabled workflow.

Cardiology's news cycle rarely slows in summer, and July 2026 was no exception.

A single population-health analysis reframed who belongs on a statin.

A new pill promised injectable-grade LDL lowering without the needle.

Five- and ten-year valve data quietly answered questions that have lingered since the earliest transcatheter trials.

And a voice-based AI agent in the cath lab offered a small but telling glimpse of where administrative medicine is headed.

Below is a condensed, practice- and portfolio-relevant synthesis of the month's highest-yield stories.

1. The 2026 Dyslipidemia Guidelines Just Made Half the Country Statin-Eligible

A new JAMA population analysis quantified what the 2026 AHA/ACC multisociety dyslipidemia guideline actually means at scale.

Using NHANES data extrapolated to 154.5 million US adults, investigators estimated that 87.5 million nonpregnant adults aged 30-79 — 56.6% of that population — now qualify for primary-prevention statin therapy.

Of those, 21.5 million are newly eligible compared with the 2018 cholesterol guideline, driven mainly by the shift to the PREVENT risk-estimation tool and extension of risk assessment down to age 30.

More than 93% of adults in their 70s and 85% of those in their 60s now meet criteria, versus just 11% of adults in their 30s.

A companion analysis found that even among patients already above LDL goal, roughly three-quarters of primary-prevention patients and over a third of secondary-prevention patients are not on any lipid-lowering therapy at all.

For the cardiologist, the guideline's real message is less "treat everyone" and more "have the conversation earlier," since newly eligible patients skew younger and carry a much lower absolute 10-year risk than those previously targeted.

Metric (ages 30-79, no known ASCVD)	2026 Guideline
Total statin-eligible adults	87.5 million (56.6%)
Newly eligible vs. 2018 guideline	21.5 million (13.9%)
Eligible, ages 70-79	>93%
Eligible, ages 60-69	85%
Eligible, ages 30-39	11%
Mean 10-yr ASCVD risk, newly eligible	3.1%

Source: NHANES-based analysis, JAMA, July 2026.

2. A Second Universal Definition of Heart Failure Retires Rigid LVEF Cutoffs

A multisociety writing group has issued the second universal definition of heart failure, building on the original 2021 framework.

The update groups heart failure into reduced, preserved, and improved ejection-fraction categories rather than anchoring management to strict LVEF thresholds.

It also proposes a more granular etiologic classification, acknowledging that phenotypes such as idiopathic cardiomyopathy may eventually be reclassified as genetic or familial disease as testing matures.

For clinicians, the practical takeaway is a documentation and coding framework that should better capture phenotype-specific trajectories, including patients whose EF has normalized on therapy (HFimpEF).

3. Burnout Hits Cardiac Imagers Especially Hard

New survey data presented at the 2026 Society of Cardiovascular Computed Tomography meeting found a distinct burnout signal among cardiovascular imaging specialists.

More than two-thirds of respondents reported working outside scheduled hours, and 37% reported doing so daily.

This "pajama time" phenomenon, layered on top of growing administrative burden, is prompting calls within the imaging community for structural rather than individual-level fixes.

For practice and health-system leaders, this is a workforce-planning signal worth tracking alongside broader physician-staffing and reimbursement trends in imaging.

4. FDA Approves the First Oral PCSK9 Inhibitor

The FDA has approved enlicitide (Lipfendra; Merck), a once-daily 20-mg tablet and the first oral PCSK9 inhibitor on the market.

The approval covers adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise.

In the Phase 3 CORALreef program, enlicitide produced placebo-adjusted LDL-C reductions of 56% (CORALreef Lipids) and 59% (CORALreef HeFH) at 24 weeks — squarely in line with injectable PCSK9 agents.

Enlicitide is a macrocyclic peptide rather than a monoclonal antibody, which is what allows oral bioavailability, and the most common adverse effects in trials were diarrhea and dizziness.

For patients who are needle-averse or face logistical barriers to injectable specialty pharmacy distribution, this changes the adherence calculus meaningfully.

Merck (NYSE: MRK) shares moved higher on the approval; as of late July 2026 the stock traded near $129-130 with a consensus analyst rating of "Buy" and an average 12-month price target in the $130-150 range, though cardiovascular contribution to Merck's broader oncology-dominated revenue base remains modest for now.

PCSK9-Class Landscape

Agent	Brand	Company (Ticker)	Route	Approx. Annual List Price*
Enlicitide	Lipfendra	Merck (NYSE: MRK)	Oral, once daily	Not yet published
Evolocumab	Repatha	Amgen (NASDAQ: AMGN)	SC injection q2-4wk	~$6,000-8,000
Alirocumab	Praluent	Regeneron (NASDAQ: REGN) / Sanofi (NASDAQ: SNY)	SC injection q2-4wk	~$5,400-6,500
Inclisiran	Leqvio	Novartis (NYSE: NVS)	SC injection, twice yearly	~$6,500-7,000
Lerodalcibep	Lerochol	LIB Therapeutics — no ticker (private)	SC injection, monthly	Not yet published

*List/WAC pricing before rebates or copay assistance; figures are time-sensitive and vary by pharmacy, insurer, and manufacturer program — verify current pricing before quoting to patients. Sources: GoodRx, Drugs.com, manufacturer statements.

5. Structural Heart: TAVI's Long Game Comes Into Focus

EARLY TAVR at 5 Years

Extended follow-up from EARLY TAVR, presented at New York Valves 2026, continues to favor prompt intervention over clinical surveillance in asymptomatic severe aortic stenosis.

At a median of 5 years, the composite of death, stroke, or heart failure hospitalization remained significantly lower with early transfemoral TAVI (15.2% vs 24.2%) using the balloon-expandable Sapien 3 platform (Edwards Lifesciences).

Death and stroke rates were similar between arms through the first 2 years, meaning early intervention carried no early penalty for that benefit.

Ten-Year PARTNER 2A / P2S3i Data

Separately, 10-year follow-up of PARTNER 2A and the Sapien 3 Intermediate Risk Registry showed generally reassuring durability for intermediate-risk patients, though all-cause mortality was modestly higher with TAVI than SAVR (86.1% vs 82.8%), a gap driven largely by outcomes in the subset treated via transthoracic access.

Investigators cautioned that incomplete re-consent for follow-up beyond 5 years limits how firmly these figures should be interpreted.

Access-Site Strategy: SAFER-TAVI

A separate NY Valves 2026 presentation on secondary access site management (SAFER-TAVI) suggested that a radial-first approach reduces vascular complications tied to secondary access, echoing the slower cultural shift toward radial-default strategies already seen in PCI.

Rhythm-Structural Crossover: STUN-AF

In atrial fibrillation patients undergoing combined ablation and appendage closure, the nonrandomized STUN-AF study found that ablating the left atrial appendage before device implantation nearly eliminated peridevice leaks at 12 months (96% leak-free vs 58%).

The mechanism appears to be reduced residual appendage contractility, and the approach is already being adopted selectively by proceduralists performing concomitant procedures, though cost remains a barrier for isolated LAAO cases.

Study	Population	Key Finding
EARLY TAVR (5-yr)	Asymptomatic severe AS	Composite endpoint 15.2% (TAVI) vs 24.2% (surveillance)
PARTNER 2A / P2S3i (10-yr)	Intermediate-risk symptomatic AS	Mortality 86.1% (TAVI) vs 82.8% (SAVR)
STUN-AF	Concomitant PFA + LAAO	Leak-free rate 96% (pre-ablation) vs 58% at 12 mo

6. Vitamin K2 Supplementation and Coronary Calcium: A Cautious Signal

The randomized VitaK-CAC trial found that daily menaquinone-7 (MK-7), a vitamin K homologue, modestly slowed coronary artery calcium progression over 2 years in patients with mild-to-moderate CAC (50-400 Agatston units).

Median CAC scores rose in both arms, but the annual increase was roughly 19 Agatston units smaller with MK-7 supplementation.

The trial enrolled only 180 patients, and experts commenting on the findings emphasized that a reduction in a calcium score is not the same as a reduction in cardiovascular events or plaque instability.

This is a reasonable topic for patient discussion but not yet a basis for a formal treatment recommendation.

7. AI Quietly Enters the Cath Lab Workflow

A pilot study of Sofiya, an AI voice agent used at Mount Sinai Hospital, showed that a conversational assistant can reliably handle preprocedural calls ahead of cardiac catheterization.

Across 806 calls, the completion rate approached 90%, more than a third were resolved without any nurse escalation, and patient satisfaction exceeded 94%.

Investigators estimated the time savings at roughly 11 minutes per call, equivalent to nearly 37 twelve-hour nursing shifts annually at a cath lab performing more than 16,000 procedures a year.

Commentators were careful to frame this as augmentation of administrative workflow rather than a substitute for clinical judgment, since most calls still required some nursing involvement.

Clinical Case Vignette

A 58-year-old accountant with a family history of premature coronary disease presents for an annual physical with an LDL-C of 165 mg/dL and a 10-year ASCVD risk of 4% by the PREVENT calculator.

Under the prior cholesterol framework she may have been considered low priority for pharmacotherapy, but her 30-year risk estimate is substantially higher given her age and family history.

Applying the 2026 dyslipidemia guideline framework, her physician initiates a moderate-intensity statin and schedules a follow-up lipid panel, explicitly framing the decision around lifetime rather than 10-year risk.

Eighteen months later, still above her LDL goal on maximally tolerated statin therapy and reluctant to self-inject, she is switched to oral enlicitide, illustrating how this month's guideline and drug-approval news intersect in a single, realistic patient encounter.

Figure 1. Share of US adults aged 30-79 meeting statin eligibility criteria under the 2026 dyslipidemia guideline, by age band. Source: NHANES-based JAMA analysis, July 2026.

Figure 2. Approximate trajectory of the composite endpoint (death, stroke, or heart failure hospitalization) in EARLY TAVR; intermediate points are illustrative interpolations between reported timepoints, not raw trial data. Source: TCTMD coverage of New York Valves 2026.

Bottom Line

The 2026 dyslipidemia guideline and the enlicitide approval are two halves of the same story: more patients now qualify for aggressive LDL-lowering, and for the first time there is a convenient oral option once statins and ezetimibe fall short.

In structural heart disease, the data keep converging on a single message — earlier, well-planned intervention in severe aortic stenosis outperforms watchful waiting, while long-term durability data remain reassuring but incomplete beyond a decade.

For investors, Merck's cardiovascular franchise now has a genuine growth story alongside its oncology base, while Edwards Lifesciences and the broader TAVI ecosystem continue to benefit from an expanding, evidence-supported patient population.

None of this changes near-term trading dynamics, but it does reinforce the durability of secular growth in both lipid management and structural heart device volumes.

Companion Content

Prefer a spoken-word summary? These recent, freely available videos cover adjacent territory well:

• TCTMD's YouTube channel — conference wrap-ups and quick-takes from New York Valves 2026 and SCCT 2026.
• Search "2026 dyslipidemia guideline explained" on YouTube for recent society-produced explainer videos aimed at clinicians.
• Search "oral PCSK9 inhibitor enlicitide mechanism" for mechanism-of-action animations from independent medical education channels.

References

1. Anderson TS, Wilson LM, Sussman JB. Implications of the 2026 dyslipidemia guideline for primary prevention statin therapy. JAMA. 2026. Covered in: TCTMD.
2. Walsh MN, Kober L, Sliwa K, et al. AHA/ACC/ESC/WHF expert consensus document: second universal definition of heart failure (2026). Covered in: TCTMD.
3. Chinnaiyan KM. Supporting the workforce: burnout and well-being in cardiac CT. Presented at SCCT 2026. Covered in: TCTMD.
4. US Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol. July 2026.
5. Généreux P. Transcatheter aortic valve replacement for asymptomatic severe aortic stenosis: latest follow-up from the EARLY TAVR trial. Presented at New York Valves 2026. Covered in: TCTMD.
6. Thourani V, et al. 10-year follow-up of PARTNER 2A and the Sapien 3 Intermediate Risk Registry. Covered in: TCTMD.
7. Reddy VY, et al. Pulsed field ablation of the LAA prior to LAA closure: the STUN-AF study. Presented at New York Valves 2026. Covered in: TCTMD.
8. Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two years of menaquinone-7 supplementation and coronary artery calcification: a randomized clinical trial (VitaK-CAC). JAMA Cardiology. 2026. Covered in: TCTMD.
9. Kini AS, Vengrenyuk A, Pineda D, et al. Utilizing an AI-assisted virtual agent for pre-procedural patient calling in the cardiac catheterization laboratory. Eur Heart J Digit Health. 2026. Oxford Academic.

Physician education disclaimer: This article is intended for licensed healthcare professionals for continuing education purposes and does not constitute individualized clinical guidance; treatment decisions should be based on full trial publications, current guidelines, and individual patient circumstances.

Financial disclaimer: This content is for informational purposes only and does not constitute investment advice; stock prices, analyst price targets, and drug pricing figures are time-sensitive, were current as of late July 2026, and should be independently verified before any investment or purchasing decision. The author is not a licensed financial advisor.

Interventional & Preventive Cardiology · Physician-Investor Briefing

Anticoagulants and Antiplatelets in 2026: A Complete Field Guide by Indication

Every major antithrombotic class in current use, mapped to the indications that drive real prescribing decisions, plus the reversal-agent shakeup and pipeline drugs worth watching.

Clinical Review·Updated July 2026·~14 min read

Cardiologists juggle two distinct antithrombotic toolkits every day: anticoagulants, which interrupt the coagulation cascade, and antiplatelets, which block platelet activation and aggregation.

The two classes are not interchangeable, and the indication almost always dictates the choice: atrial fibrillation and venous thromboembolism are anticoagulant territory, while acute coronary syndrome and percutaneous coronary intervention are built around antiplatelet therapy, often layered on top of an anticoagulant.

This briefing organizes both drug classes by mechanism and then by the clinical indication that should drive selection, and it folds in the reversal-agent shakeup from late 2025 and the factor XIa pipeline that could reshape the field again before this decade is out.

In This Article

1. Anticoagulants: Vitamin K Antagonism Through DOACs
2. Antiplatelets: Aspirin Through GPIIb/IIIa Inhibitors
3. The Reversal-Agent Landscape Just Changed
4. Quick Reference by Indication
5. What's Next: Factor XIa Inhibitors

Anticoagulants: Vitamin K Antagonism Through DOACs

Warfarin (brand names Coumadin and Jantoven) remains the only oral anticoagulant with decades of outcome data in mechanical heart valves and moderate-to-severe mitral stenosis, populations excluded from every DOAC trial.

It works by inhibiting hepatic synthesis of vitamin K–dependent clotting factors II, VII, IX, and X, which is also why it requires routine INR monitoring and carries a target range of 2.0–3.0 for most indications, or 2.5–3.5 for mechanical mitral valves.

Generic warfarin is inexpensive, typically under $10 per month at most retail pharmacies according to GoodRx pricing data, which keeps it relevant in resource-limited settings and for patients who cannot afford brand-name DOACs.

Four direct oral anticoagulants now anchor most anticoagulation decisions in nonvalvular atrial fibrillation, venous thromboembolism, and post-orthopedic prophylaxis.

Apixaban (Eliquis) remains the most widely prescribed DOAC in the United States and is now Medicare's highest-spend Part D drug, at an estimated $16.5 billion in annual program cost.

Rivaroxaban (Xarelto) offers once-daily dosing and the broadest label of the group, spanning atrial fibrillation, venous thromboembolism, and secondary prevention in stable coronary and peripheral artery disease at a reduced "vascular dose," often paired with aspirin under a dual-pathway inhibition strategy.

Dabigatran (Pradaxa) is the only DOAC dosed as a direct thrombin inhibitor rather than a factor Xa blocker, and it is the only one with a long-standing FDA-approved specific reversal agent.

Edoxaban (Savaysa in the U.S., marketed as Lixiana outside the U.S.) rounds out the class with once-daily dosing, though a label caveat limits its use in patients with very high creatinine clearance for atrial fibrillation indications.

Anticoagulant Comparison and Pricing Snapshot

Agent	Brand	Mechanism	Key Indications	GoodRx Cash Price*	Company / Ticker
Apixaban	Eliquis	Factor Xa inhibitor	AF stroke prevention, VTE tx/prevention	~$348–630/mo	NYSE: BMY NYSE: PFE
Rivaroxaban	Xarelto	Factor Xa inhibitor	AF, VTE, CAD/PAD secondary prevention	~$37 coupon low / ~$470 retail	NYSE: JNJ OTC: BAYRY
Dabigatran	Pradaxa	Direct thrombin inhibitor	AF stroke prevention, VTE tx/prevention	~$36–46/mo generic	Boehringer Ingelheim (private)
Edoxaban	Savaysa	Factor Xa inhibitor	AF (CrCl-limited), VTE tx	~$423–515/mo	OTC: DSNKY
Warfarin	Coumadin / Jantoven	Vitamin K antagonist	Mechanical valves, mitral stenosis, AF, VTE	~$4–10/mo generic	Multiple generic manufacturers

*Cash prices vary by pharmacy and are time-sensitive; figures reflect GoodRx-listed ranges as of mid-2026 and exclude insurance-negotiated or Medicare IRA prices.

Each anticoagulant class interrupts the cascade at a different point; factor XIa inhibitors target upstream amplification rather than the common pathway, which is the theoretical basis for their lower bleeding signal.

Antiplatelets: Aspirin Through GPIIb/IIIa Inhibitors

Aspirin remains the foundation of antiplatelet therapy across nearly every cardiovascular indication, irreversibly inhibiting COX-1 to block thromboxane A2–driven platelet aggregation at a cost of just a few dollars a month according to GoodRx.

The P2Y12 inhibitor class sits on top of aspirin in most acute coronary syndrome and post-PCI regimens, and the three oral agents differ meaningfully in onset, potency, and bleeding risk.

Clopidogrel (Plavix) is the least potent but cheapest and most extensively studied option, now available as a low-cost generic for as little as $4.50 per month with a coupon, though reduced-function CYP2C19 metabolizers get less benefit from it.

Ticagrelor (Brilinta) is a reversible-binding agent with faster onset and stronger platelet inhibition than clopidogrel, and it carries a Class I recommendation across most acute coronary syndrome guidelines regardless of genotype.

Prasugrel (Effient) offers the most potent platelet inhibition of the oral agents but is restricted to patients undergoing PCI and is generally avoided in those 75 years or older, under 60 kg, or with prior stroke or TIA given its bleeding profile.

Cangrelor (Kengreal) is the only intravenous P2Y12 inhibitor, valued in the cath lab for its rapid onset and equally rapid offset within about an hour of stopping the infusion, useful when oral absorption is unreliable or a bridge to surgery is needed.

The GPIIb/IIIa inhibitors — abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat) — block the final common pathway of platelet aggregation and are reserved almost exclusively for high-thrombus-burden PCI or bailout situations given their bleeding and thrombocytopenia risk.

Vorapaxar (Zontivity) is a PAR-1 antagonist added on top of aspirin and/or a P2Y12 inhibitor for secondary prevention after myocardial infarction or in symptomatic PAD, but it is contraindicated in anyone with a history of stroke, TIA, or intracranial hemorrhage.

Antiplatelet Comparison and Pricing Snapshot

Agent	Brand	Class	Route	Typical Cash Price*	Company / Ticker
Aspirin	Various	COX-1 inhibitor	Oral	~$4–7/mo	Multiple OTC manufacturers
Clopidogrel	Plavix	P2Y12 inhibitor (irreversible)	Oral	~$4.50–25/mo generic	Multiple generic manufacturers
Ticagrelor	Brilinta	P2Y12 inhibitor (reversible)	Oral	~$25–35/mo coupon	NASDAQ: AZN
Prasugrel	Effient	P2Y12 inhibitor (irreversible)	Oral	~$9–29/mo generic	OTC: DSNKY / Eli Lilly
Cangrelor	Kengreal	P2Y12 inhibitor (IV)	Intravenous	Inpatient/hospital billed	Chiesi Farmaceutici (private)
Eptifibatide	Integrilin (generic only)	GPIIb/IIIa inhibitor	Intravenous	~$31–92/vial	Multiple generic manufacturers
Tirofiban	Aggrastat	GPIIb/IIIa inhibitor	Intravenous	Inpatient/hospital billed	OTC: MCUJF
Abciximab	ReoPro	GPIIb/IIIa inhibitor	Intravenous	Inpatient/hospital billed; limited current use	Legacy branded product
Vorapaxar	Zontivity	PAR-1 antagonist	Oral	Variable, brand-only	NYSE: MRK

*IV agents are hospital-administered and typically billed as part of the procedure rather than filled at retail pharmacies; prices shown are wholesale/vial references and are time-sensitive.

Aspirin and vorapaxar act on distinct upstream activation pathways, while P2Y12 and GPIIb/IIIa inhibitors converge on the platelet surface receptors that drive final aggregation.

The Reversal-Agent Landscape Just Changed

Anyone managing DOAC-associated bleeding needs to know that andexanet alfa (Andexxa) is no longer available in the United States.

The FDA safety communication issued in December 2025 reported that the confirmatory ANNEXA-I trial found thrombotic events in 14.6% of andexanet-treated patients versus 6.9% with usual care, alongside a near-tripling of thrombosis-related death.

AstraZeneca voluntarily withdrew the biologics license and ended U.S. commercial sales on December 22, 2025, which means 4-factor prothrombin complex concentrate (Kcentra) is now the de facto standard of care for reversing apixaban- or rivaroxaban-associated life-threatening bleeding.

Idarucizumab (Praxbind) is unaffected by this withdrawal and remains the specific reversal agent for dabigatran, working as a monoclonal antibody fragment that binds free and thrombin-bound drug within minutes.

For warfarin, vitamin K (phytonadione) plus 4F-PCC remains standard for urgent reversal, and this sequence of preferred agents is now worth building into institutional bleeding protocols given the Andexxa gap.

Antiplatelet-associated bleeding has no specific pharmacologic antidote in routine use, so management centers on platelet transfusion for life-threatening hemorrhage in patients on potent P2Y12 inhibitors, mechanical hemostasis, and simply allowing the drug to wear off given the short half-lives of cangrelor and the GPIIb/IIIa agents.

Reversal Agent Quick Reference

Situation	Preferred Reversal	Notes	Company / Ticker
Dabigatran, life-threatening bleed	Idarucizumab (Praxbind)	Specific monoclonal antibody fragment; rapid onset	Boehringer Ingelheim (private)
Apixaban / rivaroxaban, life-threatening bleed	4F-PCC (Kcentra)	Now first-line since Andexxa withdrawal	OTC: CSLLY
Apixaban / rivaroxaban, historical option	Andexanet alfa (Andexxa)	Withdrawn from U.S. market Dec 22, 2025; do not order	NASDAQ: AZN
Warfarin, urgent reversal	Vitamin K + 4F-PCC	Vitamin K alone is too slow for active bleeding	Generic / CSLLY
Potent P2Y12 inhibitor, major bleed or urgent surgery	Platelet transfusion	No specific antidote exists; timing informed by drug half-life	Not applicable

Case Vignette 1: Reversal Decision

A 78-year-old on apixaban for atrial fibrillation presents with a large spontaneous intracranial hemorrhage six hours after her last dose.

Before the Andexxa withdrawal, many centers would have reached for andexanet alfa; the correct 2026 approach is immediate 4F-PCC dosed per institutional protocol, since andexanet is no longer commercially available and its risk-benefit profile no longer favored its use even before the recall.

Case Vignette 2: Antiplatelet Selection at PCI

A 61-year-old smoker presents with an NSTEMI and undergoes drug-eluting stent placement in the mid-LAD with a high thrombus burden noted on angiography.

A reasonable strategy pairs aspirin with ticagrelor for at least 12 months given its guideline-preferred status over clopidogrel in ACS, with intraprocedural cangrelor or a GPIIb/IIIa agent reserved for bailout if there is angiographic evidence of thrombus or slow flow.

Quick Reference by Indication

The single most useful organizing principle in antithrombotic therapy is matching the drug class to the clot's origin: cardiac/venous stasis clots respond to anticoagulants, while arterial/platelet-rich clots respond to antiplatelets, and several indications require both.

Indication	First-Line Class	Typical Agent(s)	Notes
Nonvalvular atrial fibrillation	Anticoagulant	Apixaban, rivaroxaban, dabigatran, edoxaban	Warfarin if mechanical valve or significant mitral stenosis
Venous thromboembolism (DVT/PE)	Anticoagulant	Apixaban or rivaroxaban (no lead-in needed)	Warfarin bridged with heparin in antiphospholipid syndrome
STEMI/NSTEMI, medically managed	Antiplatelet (dual)	Aspirin + ticagrelor or clopidogrel	Anticoagulant (heparin) added acutely, not chronically
Post-PCI with stent	Antiplatelet (dual)	Aspirin + ticagrelor, prasugrel, or clopidogrel	Duration individualized by bleeding vs ischemic risk
High thrombus burden PCI / bailout	Antiplatelet (IV)	Cangrelor or a GPIIb/IIIa inhibitor	Reserved for high-risk or complex lesions
Secondary stroke/TIA prevention (non-cardioembolic)	Antiplatelet	Aspirin, clopidogrel, or short-course dual therapy	Factor XIa inhibitors under regulatory review for this space
Stable CAD or symptomatic PAD	Antiplatelet ± anticoagulant	Aspirin or clopidogrel; low-dose rivaroxaban + aspirin in select patients	Dual-pathway inhibition per the COMPASS trial strategy
Mechanical heart valve	Anticoagulant	Warfarin	DOACs are contraindicated in this population
LVAD / mechanical circulatory support	Anticoagulant + antiplatelet	Warfarin plus aspirin	Device-specific protocols apply

What's Next: Factor XIa Inhibitors

The next anticoagulant class targets factor XI/XIa, a node in the intrinsic pathway that appears to contribute more to pathological clot amplification than to normal hemostasis.

Asundexian (Bayer) is furthest along regulatory-wise: it received FDA Priority Review in May 2026 for secondary stroke prevention after non-cardioembolic ischemic stroke or high-risk TIA, based on the OCEANIC-STROKE trial, though it does not yet have routine approval for any indication.

Abelacimab (Anthos Therapeutics, a privately held company with no public ticker) posted a striking safety signal in the Phase 2b AZALEA-TIMI 71 trial, cutting major or clinically relevant non-major bleeding by 62% compared with rivaroxaban in patients with atrial fibrillation.

Its Phase 3 efficacy readout, the LILAC-TIMI 76 stroke-prevention trial, is tracked publicly on ClinicalTrials.gov and represents the pivotal data investors and clinicians are both watching.

Milvexian (Bristol Myers Squibb and Johnson & Johnson) is being tested across multiple settings, including the post-acute coronary syndrome population in the LIBREXIA-ACS program, positioning it as a potential add-on to antiplatelet therapy rather than a stand-alone AF drug.

The shared thesis across this class, summarized well by recent pharmacy literature, is a safer alternative to DOACs with similar efficacy and materially reduced bleeding, though as of this writing none has full U.S. approval for a cardiovascular indication.

Factor XIa Inhibitor Pipeline Snapshot (July 2026)

Agent	Modality	Lead Indication	Regulatory Status	Company / Ticker
Asundexian	Oral small molecule	Secondary stroke prevention post-TIA/stroke	FDA Priority Review (accepted May 2026)	OTC: BAYRY
Abelacimab	Monoclonal antibody	AF stroke prevention	Phase 3 (LILAC-TIMI 76) ongoing	Anthos Therapeutics (private)
Milvexian	Oral small molecule	Post-ACS secondary prevention	Phase 3 (LIBREXIA program) ongoing	NYSE: BMY NYSE: JNJ

Practical Takeaways for Clinical Decision-Making

Choice among the four current DOACs still hinges on renal function, drug interactions, and cost, with apixaban generally preferred in patients with higher bleeding risk based on its trial-level safety profile.

Warfarin remains non-negotiable for mechanical valves and moderate-to-severe mitral stenosis, where no DOAC has demonstrated safety or efficacy.

Ticagrelor or prasugrel are generally preferred over clopidogrel after ACS in patients without a bleeding contraindication, though clopidogrel remains reasonable for elderly or high-bleeding-risk patients.

Every institution should update its massive-bleeding and reversal protocols now to remove Andexxa as an option and substitute 4F-PCC as first-line for factor Xa inhibitor–associated bleeding.

Factor XIa inhibitors are not yet prescribable for any cardiovascular indication in the U.S. as of July 2026, but asundexian's Priority Review timeline suggests a possible approval decision within this cycle, worth flagging for both clinical planning and portfolio watchlists.

Bottom Line

Anticoagulants own atrial fibrillation and venous thromboembolism, antiplatelets own acute coronary syndrome and PCI, warfarin persists for valve disease, the Andexxa withdrawal has quietly made 4F-PCC the default reversal strategy for factor Xa inhibitors, and factor XIa inhibitors led by asundexian and abelacimab are the space to watch for a potentially lower-bleeding anticoagulant future.

Watch Next

• Factor XI Inhibitors Explained — search results, YouTube
• DOAC Reversal Strategies After Andexxa Withdrawal — search results, YouTube
• Dual Antiplatelet Therapy Duration After PCI — search results, YouTube
• AZALEA-TIMI 71 Abelacimab Data Review — search results, YouTube

References

1. FDA Safety Communication: Update on the Safety of Andexxa, December 18, 2025.
2. Bayer: FDA Accepts NDA for Asundexian Under Priority Review, May 2026.
3. HCPLive: Abelacimab Limits Bleeding Events in AZALEA-TIMI 71.
4. Pharmacy Times: Factor XI Inhibitors — The Future of Anticoagulation.
5. ClinicalTrials.gov: AZALEA-TIMI 71 / LILAC-TIMI 76 Study Record.
6. TCTMD: New AF Guideline Emphasizes Early Rhythm Control.
7. GoodRx: Antiplatelet Drugs Class Overview, 2026.
8. GoodRx: Blood Thinner Medications Pricing Overview, 2026.

Physician education disclaimer: This article is intended for licensed healthcare professionals as a clinical education summary and does not replace institutional protocols, full prescribing information, or individualized patient assessment.

Financial disclaimer: Ticker symbols and pricing figures are provided for thematic and educational context only, reflect a specific point in time, and do not constitute investment advice or a recommendation to buy or sell any security; consult a licensed financial advisor before making investment decisions.

Cardiology & Capital Markets Briefing · For medical professional audiences

Structural Heart · Physician-Investor Briefing

Age and Early TAVR for Asymptomatic Severe Aortic Stenosis: What the Latest Data Mean for Practice and Portfolios

A closer look at how patient age reshapes the risk-benefit calculus of early intervention, and what it signals for the companies behind the valves.

Cardiology · Structural Heart Disease · 8 min read

Case Vignette

A 68-year-old asymptomatic executive with severe aortic stenosis and a peak aortic jet velocity of 4.6 m/s asks whether he should wait for symptoms or proceed now, since he feels completely well and has an upcoming board meeting he does not want to miss. His Society of Thoracic Surgeons risk score is low, his stress test is negative, and his echocardiogram shows preserved ejection fraction. This is precisely the scenario in which age-stratified trial data now offer a clearer answer than watchful waiting once did.

The Old Paradigm Is Cracking

For six decades, guidelines told clinicians to wait for symptoms before replacing a severely stenotic aortic valve.

That approach assumed intervention carried enough procedural risk to offset the danger of a diseased valve sitting quietly inside the heart.

Transcatheter aortic valve replacement has changed that math by making the procedure fast, minimally invasive, and remarkably low-risk in appropriately selected patients.

The randomized EARLY TAVR trial tested this shift directly by randomizing 901 asymptomatic patients with severe AS to either early intervention or guideline-recommended surveillance.

Primary Results at a Glance

Outcome	Early TAVR (n=455)	Clinical Surveillance (n=446)
Composite: death, stroke, or unplanned CV hospitalization	26.8%	45.3%
Death	8.4%	9.2%
Stroke	4.2%	6.7%
Unplanned CV hospitalization	20.9%	41.7%
Crossed over to AVR by 3.8 years	—	87.0%

The hazard ratio for the primary composite endpoint was 0.50, meaning early intervention roughly halved the risk compared with waiting for symptoms to appear.

Nearly nine in ten patients assigned to surveillance eventually needed valve replacement anyway, just later and after accumulating more risk along the way.

Figure 1. Key EARLY TAVR outcomes at a median follow-up of 3.8 years.

Why Age Changes the Answer

A late-breaking analysis presented at the Society for Cardiovascular Angiography and Interventions 2025 meeting asked whether a patient's age should influence the timing decision.

Older age was associated with higher rates of death, stroke, or heart failure hospitalization out to five years in both study arms, which is unsurprising on its own.

What stood out was that the relative benefit of early intervention was not confined to the elderly; it was substantial across the age spectrum, including the youngest enrolled patients.

Age-Stratified Benefit of Early TAVR

Age Group	Standout Finding at 5 Years
65–69 years	Stroke risk 0% with early TAVR vs 13% with surveillance; roughly six-fold lower rate of death, stroke, or hospitalization (4.7% vs 25.6%)
70–79 years	Consistent directional benefit with early TAVR across the composite endpoint
>80 years	Four-fold reduction in stroke with early TAVR compared with surveillance

The takeaway from the trial's lead investigators was that early TAVR should be favored over surveillance across essentially all age groups above the trial's 65-year inclusion threshold, since the composite endpoint consistently favored intervention.

This matters clinically because many physicians have intuitively reserved early intervention for older, frailer patients rather than younger ones who "still feel fine."

The data suggest the opposite framing may be more accurate: younger asymptomatic patients with severe AS may have the most to gain from acting early, particularly with respect to stroke prevention.

Figure 2. Simplified decision pathway informed by EARLY TAVR age-stratified findings.

The Market Side: Who Builds These Valves

The trial's balloon-expandable device is Edwards Lifesciences' SAPIEN platform, and the company remains the dominant player in transfemoral TAVRNYSE: EW.

Medtronic's self-expanding Evolut platform is the other major branded competitor in this spaceNYSE: MDT.

Expanding the addressable population from symptomatic to asymptomatic severe AS could meaningfully widen the eligible patient pool for both companies, since asymptomatic severe AS is common in aging populations and previously went untreated until symptoms emerged.

Structural Heart Device Makers at a Glance

Company	Ticker	Relevant Platform	Analyst Consensus	12-Month Price Target
Edwards Lifesciences	NYSE: EW	SAPIEN transcatheter valve family	Buy (27 analysts)	~$100.60 (+21% from current)
Medtronic	NYSE: MDT	Evolut self-expanding valve family	Buy (29 analysts)	~$97.84 (+16% from current)

Edwards reported second-quarter 2026 TAVR sales growth of roughly 10.5%, with overall company revenue guidance raised for the year, reflecting continued structural heart momentum even as the stock trades well below its 52-week high.

Both companies' near-term growth narratives depend partly on guideline committees eventually endorsing a broader "treat earlier" posture for asymptomatic severe AS, since current guidelines still center on symptom onset or biomarkers of decompensation as triggers for intervention.

What the Procedure Actually Costs

Cost Component	Approximate Figure
Device cost (SAPIEN 3 valve system)	~$30,000–$32,500
Median Medicare payment, full procedure	~$37,865
Median commercial insurance price	~$71,312 (varies ~2.6x by hospital and ~1.9x by insurer)
Median cash price	~$78,000

These figures come from a 2024 Circulation abstract analyzing the Turquoise Health pricing database, which found substantial regional and payer-level variation in what TAVR actually costs a given patient or system.

Extending early intervention to a much larger asymptomatic population raises legitimate health-system cost questions even though individual clinical outcomes favor earlier treatment.

Bottom Line

Age alone should no longer be the deciding factor in whether an asymptomatic patient with severe AS gets early TAVR, since benefit was consistent from the youngest enrolled patients through those over 80. The composite outcome data support a strategy shift toward earlier intervention in appropriately selected, low-surgical-risk patients rather than waiting for symptoms or crossover, which occurred in 87% of the surveillance group anyway. For the executive in the vignette above, a 68-year-old with a negative stress test and low surgical risk sits squarely inside the population that appears to benefit most, particularly regarding stroke prevention.

Physician Education Disclaimer: This article is intended for medical education purposes for physician readers and does not constitute individualized clinical guidance; treatment decisions should follow current professional society guidelines and shared decision-making with each patient.

Financial Disclaimer: Stock prices, analyst price targets, and financial data referenced above are approximate, time-sensitive, and change frequently; this content is for informational purposes only and does not constitute investment advice, and readers should consult a licensed financial advisor before making investment decisions.

Videos

NEJM: Early TAVR for Asymptomatic Severe Aortic Stenosis — trial overview

References

1. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis, New England Journal of Medicine.
2. EARLY TAVR and EVOLVED: Early Intervention in Patients With Asymptomatic AS?, American College of Cardiology.
3. EARLY TAVR Analysis Measures Influence of Patient Age on Outcomes, Cardiac Interventions Today / SCAI 2025.
4. Prices for Transcatheter Aortic Valve Repair Vary Significantly by US Insurance Company, Circulation.
5. A Review of the Cost Effectiveness of TAVR Versus SAVR, PMC.
6. Edwards Lifesciences (EW) Stock Overview, StockAnalysis.com.
7. Medtronic (MDT) Stock Overview, StockAnalysis.com.

This article synthesizes publicly available clinical trial data, professional society summaries, and financial market data current as of late July 2026 for a physician-investor audience.